18 completed, 4 unknown, 2 active not recruiting, 1 recruiting. 8 Phase 4, 7 Not applicable, 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 4, Unknown 2, Suspended 1, Withdrawn 1 |
| Not applicable | 7 | Completed 6, Unknown 1 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Extravasation of Diagnostic and Therapeutic Materials: new trials by email Literature Review of Extravasation of Diagnostic and Therapeutic Materials trials Research Report on Extravasation of Diagnostic and Therapeutic Materials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV Cabotegravir long-acting, Lenacapavir long-acting - HIV Infections | Phase 1 | Active not recruiting | ViiV Healthcare | 65 | 2025-04-22 | 2025-11-28 |
| Risk Prediction Model for Iodinated Contrast Medium Extravasation Extravasation of Contrast Media | Recruiting | Zhang Wenyan | 1000 | 2025-01-25 | 2025-03-05 | |
| Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine. Human Immunodeficiency Virus Infection (HIV), HIV-1 Infection in Adults | Active not recruiting | FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE | 3346 | 2024-12-31 | 2026-07-14 | |
| DECT for Differentiating Intracerebral Hemorrhage From Contrast Extravasation Dual Energy CT - Stroke, Ischemic, Tomography, X-Ray Computed | Not applicable | Completed | University of Manitoba | 189 | 2023-10-17 | 2026-05-01 |
| Prospective Study to Assess Tissue Responses After Injection With Biostimulatory Products Injection - Injection Site Reaction | Not applicable | Completed | Merz North America, Inc. | 20 | 2023-09-08 | 2026-09-22 |
| Differentiating Between Brain Hemorrhage and Contrast Ischemic Stroke | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 500 | 2023-09-01 | 2023-09-13 | |
| Safety of Pediatric COVID-19 Vaccination Observational - Pain, Injection Site Reaction | Completed | Duke University | 299 | 2022-04-06 | 2026-07-01 | |
| Simultaneous mRNA COVID-19 and IIV4 Vaccination Study mRNA COVID-19, IIV4, Placebo (saline) - Quality of Life, Injection Site Reaction | Phase 4 | Completed | Duke University | 348 | 2021-10-04 | 2024-03-19 |
| Simultaneous RZV and aIIV4 Vaccination FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX® - Pain, Quality of Life | Phase 4 | Completed | Duke University | 267 | 2021-09-21 | 2024-07-11 |
| Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination exercise - Vaccines, Adverse Effects, Injection Site Reaction | Not applicable | Completed | Bursa Yuksek Ihtisas Training and Research Hospital | 401 | 2021-09-01 | 2022-01-11 |
| Sorrel 25R Injector - Sorrel Clinical Study Protocol Sorrel Wearable Injector - Injection Site, Injection Site Reaction | Not applicable | Unknown | Eitan Medical | 20 | 2021-08-23 | 2022-02-03 |
| Naldebain and Video-assisted Thoracoscopic Surgery Nalbuphine Sebacate or Sesame oil (placebo) - Analgesia, Nausea and Vomiting, Postoperative | Phase 4 | Unknown | Kaohsiung Medical University Chung-Ho Memorial Hospital | 60 | 2021-07-07 | 2024-03-21 |
| Can Epinephrine Coated Syringe for Subcutaneous Immunotherapy (SCIT) Reduce Large Local Reaction? Epinephrine or normal saline - Injection Reactions Site, Systemic Reactions | Phase 1 / Phase 2 | Completed | Mahidol University | 17 | 2018-10-24 | 2020-02-20 |
| A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b - Multiple Sclerosis, Relapsing-Remitting | Completed | Biogen | 626 | 2017-11-27 | 2019-09-25 | |
| Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects Plegridy, Prednisone, Tylenol Pill - Multiple Sclerosis | Phase 4 | Unknown | Holy Name Medical Center, Inc. | 50 | 2017-09-25 | 2019-08-15 |
| FLUAD® vs. Fluzone® High-Dose Study FLUAD®, Fluzone® High-Dose - Pain, Quality of Life | Phase 4 | Completed | Duke University | 757 | 2017-08-28 | 2021-03-30 |
| Study of Iodine Contrast Media Extravasation Dry heat, Dry cold - Contrast Media Extravasation | Not applicable | Completed | Hospital de Sant Pau | 65 | 2017-06-06 | 2021-02-16 |
| A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers. Sodium chloride - Injection Site Reaction | Phase 4 | Completed | Aspen Global Incorporated | 15 | 2016-06-02 | 2019-02-15 |
| Brimonidine Tartrate for the Treatment of Injection Related Erythema peginterferon beta-1a, brimonidine tartrate, Vehicle Gel - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 4 | Withdrawn | Biogen | 2016-02-01 | 2016-04-25 | |
| Transgender, Silicone and Blood Smear Injection; Complications, Sepsis, Injection Site Disorder | Completed | Assistance Publique - Hôpitaux de Paris | 66 | 2015-07-01 | 2016-01-25 |
Showing 20 of 28. Sign in to see all of them.
Injection Site Reaction (20) · Drug-Related Side Effects and Adverse Reactions (4) · Influenza, Human (3) · Pain (3) · Acquired Immunodeficiency Syndrome (2) · Agnosia (2) · Ischemic Stroke (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Behavior (1) · COVID-19 (1) · Cerebral Hemorrhage (1) · Demyelinating Diseases (1) · Diabetes Mellitus, Type 2 (1) · Ecchymosis (1)
Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Chemically-Induced Disorders (20) · Drug-Related Side Effects and Adverse Reactions (16) · Wounds and Injuries (9) · Infections (7) · Nervous System Diseases (7) · Signs and Symptoms (7) · Immune System Diseases (6) · RNA Virus Infections (6) · Virus Diseases (6) · Neurologic Manifestations (5) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3)
peginterferon beta-1a (3) · Influenza Vaccines (2) · Saline Solution (2) · Sodium Chloride (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Acetaminophen (1) · Brimonidine Tartrate (1) · Epinephrine (1) · Exercise (1) · Heparin (1) · ISIS-113715 (1) · Injections (1) · Interferon beta-1a (1) · Interferon beta-1b (1) · Prednisone (1)
Duke University (4) · Biogen (2) · Anand Prasad (1) · Aspen Global Incorporated (1) · Assistance Publique - Hôpitaux de Paris (1) · Bursa Yuksek Ihtisas Training and Research Hospital (1) · CW Optics, Inc. (1) · Canadian Immunodeficiency Research Collaborative (1) · Eitan Medical (1) · FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE (1) · Holy Name Medical Center, Inc. (1) · Hospital M'Boi Mirim (1) · Hospital de Sant Pau (1) · Ionis Pharmaceuticals, Inc. (1) · Istanbul Saglik Bilimleri University (1)
United States (10) · Spain (3) · Canada (2) · Brazil (1) · China (1) · France (1) · Germany (1) · Italy (1) · Taiwan (1) · Thailand (1) · Turkey (Türkiye) (1)
Kenneth Schmader, MD (2) · Ann P Marx, MD (1) · Darcy Doellman, RN (1) · Elizabeth Barnett, MD (1) · Elizabeth Schlaudecker, MD, MPH (1) · Emmanuel B Walter, MD, MPH (1) · Fabrice Bouscarat, MD (1) · Filippo Festini, RN, BSN, MSN (1) · Hung-Te Hsu, MD, PhD (1) · Karen R Broder, MD (1) · Kawsar Talaat, MD (1) · Luiz Carlos R Lamblet, Nurse (1) · Marc C Torjman (1) · Mark K Wedel, MD, JD, FACP (1)
PMID 15304586, PMID 17588298, PMID 17650835, PMID 21195945, PMID 22030569, PMID 26263287, PMID 33443580, PMID 37393237, PMID 37781954, PMID 39446325, PMID 39504023, PMID 40382572, PMID 41380398, PMID 9633761
2015 (1), R44HL062008 (1)